Drug Combo Better than Single Agent in EGFR, MET-Mutated NSCLC

Combination therapy with the EGFR inhibitor osimertinib and the MET tyrosine kinase inhibitor savolitinib significantly improves outcomes for patients with EGFR-mutant, MET-aberrant non–small cell lung cancer compared with osimertinib monotherapy. However, future studies including a cohort of patients with EGFR but not MET mutations are needed to definitively determine whether MET aberrance is an indicator of poor prognosis.